DaVita Clinical Research Study Indicates Efficacy of COVID-19 mRNA Vaccines in Dialysis Patients

Research supports vaccination as an important clinical strategy to help protect vulnerable patients from viral infection.

DENVER, November 29, 2021 /PRNewswire/ — Dialysis patients who received mRNA vaccines against COVID-19 had a lower risk of being diagnosed with COVID-19 after vaccination and were less likely to be hospitalized or die after a breakthrough infection than unvaccinated patients, according to a DaVita Clinical Research (DCR) study published online ahead of print by the Journal of the American Society of Nephrology.

“This is the first large study to understand the clinical effectiveness of COVID-19 vaccines in this highly vulnerable patient population,” said Dr. steven brunelli, MCSE, Vice President of DCR. “Our findings provide reassurance that COVID-19 mRNA vaccination is an effective clinical strategy to help protect these patients against COVID-19 and associated hospitalizations and deaths.”

More than 500,000 Americans diagnosed with end-stage kidney disease (ESKD) are receiving lifesaving dialysis care. Although at high risk for COVID-19 due to underlying health conditions that compromise their immune system, these patients were not represented in the Phase III clinical trials of BNT162b (Pfizer/BioNTech) and mRNA-1273 (Moderna) SARS-CoV-2 vaccines.

To assess the effectiveness of the COVID-19 vaccine in this patient population, researchers assessed the electronic health records of 35,206 DaVita dialysis patients vaccinated with Pfizer/BioNTech or Moderna vaccines. between January 1 and February 25, 2021. These patients were matched to unvaccinated control groups and followed over time to observe future COVID-19 infections and associated clinical outcomes.

The researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective, respectively, in preventing COVID-19 infections. The study indicated that vaccinated dialysis patients who experienced breakthrough COVID-19 infection were also less likely to be hospitalized or die from COVID-19 compared to unvaccinated patients diagnosed with COVID-19. Additionally, among vaccinated dialysis patients, SARS-CoV-2 antibodies were detected at rates similar to those seen in larger phase III clinical trials.

Since the start of the COVID-19 pandemic, DCR has conducted several studies to better understand how the novel coronavirus behaves in medically vulnerable patients with ESKD. Related research efforts also include two prospective studies in patients with ESKD: one investigating the influence of prior infection/naturally acquired antibodies on future risk of infection, and a second (in course) investigating the genetic basis of susceptibility to more severe cases of COVID-19. 19.

To learn more about DaVita Clinical Research, visit DaVitaClinicalResearch.com.

About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is the research arm of DaVita. DCR innovates through retrospective research aimed at improving clinical outcomes. DCR assists pharmaceutical and medical device companies in the design, recruitment and execution of clinical trials using its network of renal research sites. To learn more about DCR, visit DaVitaClinicalResearch.com.

About DaVita Inc.
DaVita (NYSE: DVA) is a healthcare provider focused on transforming the delivery of care to improve the quality of life for patients around the world. The company is one of the largest providers of kidney care services in the United States and has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every step and step of their kidney health journey, from slowing the progression of kidney disease to assisting with transplant support, from acute hospital care to home dialysis. As of September 30, 2021, DaVita served 203,000 patients at 2,822 outpatient dialysis centers in the United States. The company also operated 333 outpatient dialysis centers in ten countries around the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable, high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Contact information
Media:
Halie Peddle
(303) 550-6349
[email protected]

Quote View original content to download multimedia: https://www.prnewswire.com/news-releases/davita-clinical-research-study-indicates-effectiveness-of-mrna-covid-19-vaccines-in-dialysis-patients -301432614.html

SOURCE DaVita Clinical Research


Company Codes: NYSE: DVA

Paul N. Strickland